Brief: Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex

IRulya Therapeutics

15/08/2024 12:04

Aug 15 (Reuters) - Quince Therapeutics Inc  QNCX.O :
    * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY
PUBLICATION
OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE
TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)
    * QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN
Q4 OF
2025
    * QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO
FDA &
MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026

Source text for Eikon:  ID:nBw4LS39za 
Further company coverage:  QNCX.O 

 (Reuters.Briefs@thomsonreuters.com)